Information for Connecticut Prescribers of Prescription Drugs:
MIMRYLO™ (rusfertide) for injection

● Connecticut law* requires that pharmaceutical representatives engaged in legend drug marketing in Connecticut disclose to prescribing practitioners and pharmacists:

- The list price of the legend drug marketed (see below).
- Information on variation efficacy of the legend drug marketed to different racial and ethnic groups, if such information is available. Please consult the product's FDA-approved label and indication for FDA-approved information regarding such, if available. The FDA-approved labeling can be found here www.mimrylohcp.com For further information, please contact Takeda's Medical Information Department at 1-877-TAKEDA-7 (1-877-825-3327) or **medinfoUS@takeda.com**.

● The list prices listed below are Wholesale Acquisition Costs (WAC) which are made available to the public by third-party publishers. Information about WAC of the drug(s) listed below is being provided to Connecticut prescribers and pharmacists pursuant to Connecticut law.

● The prices listed here reflect the list prices for the dosages and quantities described. List prices do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. WAC does not reflect discounts, rebates and other reductions in price. The actual price paid by patients may differ and is dependent upon the individual patient's insurance.

Product Name	NDC	Quantity	WAC
MIMRYLO Injection Kit (1 vial, 1 syringe) 9.5 MG	63020-0715-10	1 vial	$4,231.00
MIMRYLO Injection Kit (1 vial, 1 syringe) 19 MG	63020-0725-20	1 vial	$4,231.00
MIMRYLO Injection Kit (1 vial, 1 syringe) 28 MG	63020-0735-30	1 vial	$4,231.00
MIMRYLO Injection Kit (1 vial, 1 syringe) 41 MG	63020-0745-40	1 vial	$4,231.00
MIMRYLO Injection Kit (1 vial, 1 syringe) 54 MG	63020-0765-60	1 vial	$4,231.00

As detailed in CT HB 6669

MIMRYLO is a trademark of Takeda Pharmaceuticals U.S.A., Inc.
©2026 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved. 10/2026 US-RUS-0108